AACR Annual Meeting 2026
April 17–22, 2026 · San Diego · 2418 items
← MRD / ctDNA / DTP: from detection to treatment decisions
#LIQUIDBIOPSY
3 people · 3 posts
Heat trend for this story
Heat now 1·Peak in the comparable set 1 (Apr 22 01:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted1
Heat over time
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.
CheckMate 77T used this path: 75% clearance on nivolumab versus 46% on placebo.
Records
| Drug / trial | Readout | Setting |
|---|---|---|
| CheckMate 77Tnivolumab#LIQUIDBIOPSY#NSCLC | ctDNA clearance 75% vs 46%; clearers ~70% pCR, non-clearers ~0% | Perioperative NSCLC · nivo |
| Predicta#LIQUIDBIOPSIES#LIQUIDBIOPSY | Claimed sensitivity 1 in 10⁶ | WGS ultrasensitive ctDNA |
| NSABP-B-59#BREASTCANCER#LIQUIDBIOPSY | Tumor-informed WES predicted non-pCR and distant recurrence | Post-neoadjuvant TNBC · also under breast |
Floor
LUNGevity Foundation@LUNGevityScore6060